Abstract library

85 results for "gep-nen".
#398 Ileal GEP-NEN in Mother and Son – Option for Familial Disease
Introduction: Familial cases of ileal GEP-NEN have been described on some few occasions in the literature. Speculations of familial disease with or without a relationship to MEN-1 or other inherited endocrine neoplasias have been made
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Joakim Hennings
#3051 Epidemiology, Pathological and Clinical Features of 4307 Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of the Spanish Neuroendocrine Cancer Registry (R-GETNE)
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Rocio Garcia Carbonero
#1598 The Exploration of the Clinical Value of Plasma CgA in Nonfunctional Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: Controversies still remain on the clinical value of CgA.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: Yang Lv
Authors: Lv Y, Han X, Mao W, Zhou J, ...
#1788 Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan
Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Kazuhiro Toriyama
Keywords: prop-up, japan, gep-nen
#2839 The Second Revision of Clinical Practice Guidelines in GEP-NEN in Japan
Introduction: Japanese Neuroendocrine Tumor Society (JNETS) has published the first edition of clinical practice guidelines in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) in 2015. Then, according to an update on the diagnosis and management of GEP-NEN in Japan. Revised clinical practice guidelines, the second edition, has just published in 2019.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD, PhD Tetsuhide Ito
Authors: Ito T, Masui T, Komoto I, ...
Keywords: GEP-NEN, Guideline, Japan
#1121 Epidemiology and Classification of Gastroenteropancreatic Neuroendocrine Neoplasms Using the WHO 2010 Criteria: A Cohort Study in a Defined Norwegian Population.
Introduction: Incidence figures of gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) still remain uncertain.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Oddvar Sandvik
Keywords: GEP-NEN, epidemiology, WHO
#1397 The Relation Between GEP-NEN Prognosis Re-Stratification and Ki-67 Variability: From a Single Institution Study
Introduction: Ki-67 has been identified as a prognostic factor for GEP NEN.The variability of Ki-67 during the disease course has been reported,but there's few about its effects on prognosis.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: Zhang Qin
Authors: Rong L, Qin Z, ...
#1404 The Proteasome Inhibitor Bortezomib Is a Highly Effective Treatment Option for Gastroenteropancreatic Neuroendocrine Neoplasms and Sensitizes to DNA Damaging Therapy In Vitro
Introduction: Gastroenteropancreatic neuroendocrine neoplasms are fairly rare tumors with very heterogeneous behavior and molecular characteristics. Their generally slow proliferation render them virtually resistant to many DNA damaging therapeutic approaches. Bortezomib has been shown to be effective in GEP-NENs in vitro but has been withdrawn from clinical assessment due to a small phase II study on bortezomib monotherapy in 2004.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Franziska Briest
#1507 The CDK4/6 Inhibitor Palbociclib Induces Anti-proliferative Mechanisms in Gastroenteropancreatic Neuroendocrine Neoplasms In Vitro
Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with heterogeneous molecular backgrounds and mostly unknown druggable driver mutations. Especially for the midgut NENs effective treatment options are limited. The retinoblastoma pathway is often inactive due to CDK4/6 overexpression in pancreatic NENs. Palbociclib is a FDA approved (ER-positive and HER2-negative breast cancer) cyclin-dependent kinases 4 and 6 inhibitor and might impair cell cycle progression and proliferation.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Franziska Briest
#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study
Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Massironi